MRM/SRM assay for death receptor 5 protein
Specific peptides, and derived ionization characteristics of those peptides from Death Receptor 5 (DR5) protein are provided that are particularly advantageous for quantifying the DR5 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from a biological sample using the Liquid Tissue™ reagents and protocol, and the DR5 protein are quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described for one or more of the DR5 protein. These peptides can be quantitated if they reside in a modified or in an unmodified form. An example of a modified form of a DR5 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
1. A method for measuring the amount of the Death Receptor 5 (DR5) protein in a human biological sample of formalin-fixed tissue, comprising detecting and quantifying the amount of a DR5 fragment peptide in a protein digest prepared from said human biological sample using mass spectrometry, wherein the DR5 fragment peptide has the sequence of SEQ ID NO:1; and calculating the level of modified or unmodified DR5 protein in the sample; wherein the amount is a relative amount or an absolute amount, wherein detecting and quantifying the amount of said DR5 fragment peptide in said protein digest indicates the presence of DR5 protein and an association with cancer in the subject.
2. The method of claim 1 , further comprising correlating the results of detecting and quantifying the amount of said DR5 fragment peptide, or the amount of the DR5 protein to the diagnostic stage/grade/status of the cancer.
3. The method of claim 2 , wherein correlating the results of detecting and quantifying the amount of said DR5 fragment peptide, or the amount of the DR5 protein to the diagnostic stage/grade/status of the cancer is combined with detected and/or quantified amounts of other proteins, or peptides from other proteins, in a multiplex format to provide additional information about the diagnostic stage/grade/status of the cancer.